Venus Remedies has been awarded a tender by UNICEF for supplying ceftriaxone (1gm), a beta-lactam antibiotic, in dry powder form. Ceftriaxone dry powder is an important drug in Venus Remedies’ extensive antibiotic portfolio. Moreover, ceftriaxone is an important antibiotic globally due to its broad-spectrum activity and effectiveness in treating a variety of serious bacterial infections. The global ceftriaxone market was valued at US$ 1.7 billion in 2021 and is expected to grow at a CAGR of 2.9% from 2022 to 2031 to reach over US$ 2.2 billion by the end of 2031.
GSK Posts Positive Phase III Gonorrhea Results for Antibiotic Gepotidacin
Enforcement Report - Week of May 24, 2023
Hasten Biopharmaceutic has acquired the commercial rights in China for Rocephin, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Following the closing of the transaction earlier this year, there will be a transition period between Hasten and Roche.
Enforcement Report - Week of February 22, 2023
Biotrakson withdrawn from the market. Quality defect
The Union commerce ministry has initiated anti-dumping investigation concerning imports of active pharmaceutical ingredient (API) ceftriaxone sodium sterile exported from China following complaints by domestic firms-- Nectar Life Sciences and Sterile India.
Taiwan's Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, has announced that the first patient with severe COVID-19 demonstrated remarkable recovery after treatment with the Company's investigational drug, Silmitasertib.
Cipla Limited announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited (“VRL”) for the Indian market to further strengthen its presence in the branded Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR).
New Delhi: Indian drug majors Lupin, Sun Pharma and Glenmark Pharmaceuticals are recalling various drugs from the US market for a variety of reasons. As per the latest Enforcement Report published by the US Food and Drug Administration (USFDA), Lupin is voluntarily recalling 55,000 vials and 1,60,241 boxes of anti-bacterial drug Ceftriaxone for injection in various strengths.